Missing data in confirmatory clinical trials.

@article{Flyer2009MissingDI,
  title={Missing data in confirmatory clinical trials.},
  author={Paul Flyer and Joseph Hirman},
  journal={Journal of biopharmaceutical statistics},
  year={2009},
  volume={19 6},
  pages={969-79}
}
Missing data for key efficacy and safety endpoints in clinical trials have the potential to undermine the scientific integrity of the study and prevent definitive conclusions regarding the safety and efficacy of an experimental product. Much of the missing data is the result of poor protocol design and a lack of agreement in the scientific community regarding the collection of study data after treatment discontinuation instead of an inability to collect the data. Rather than dealing with the… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
12 Extracted Citations
14 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 12 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 14 references

Guidance for Industry

  • Food, Drug Administration.
  • Diabetes Mellitus: Developing Drugs and…
  • 2008

Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation

  • Committee for Medicinal Produces for Human Use, European Medicines Agency.
  • http://www.emea.europa.eu/pdfs/human/ewp…
  • 2008

Statistical Review and Evaluation—Temsirolimus

  • Shan, S.-M.
  • Food and Drug Administration NDA 22-088. http…
  • 2007

Clinical Team Leader Memo—Retapamulin Ointment, 1

  • J. Mulinde
  • Food and Drug Administration NDA 22-055. http…
  • 2006

Clinical Review—Exenatide Injection

  • K. E. Gabry
  • Food and Drug Administration NDA 21-733. http…
  • 2005

Statistical Review and Evaluation—Cinacalcet HCI

  • J. Mele
  • Food and Drug Administration NDA 21-688. http…
  • 2003

Statistical Review and Evaluation—Rosuvastatin Calcium

  • C. Liu
  • Food and Drug Administration NDA 21-366. http…
  • 2003

Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Diabetes Mellitus

  • European Agency for the Evaluation of Medicinal Products, Evaluation of Medicines for Human Use.
  • http://www.emea.europa.eu/pdfs/ human/ewp…
  • 2002

Statistical Review and Evaluation—Lopinavir/ritonavir

  • R. Bhore
  • Food and Drug Administration NDA 21-226/21-251…
  • 2002

Statistical Review and Evaluation—Memantine

  • T. Massie
  • Food and Drug Administration NDA 21-487. http…
  • 2002

Similar Papers

Loading similar papers…